Article info
PDFTherapeutics/Prevention
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease
- Correspondence to : Dr André J Scheen, Division of Diabetes, Nutrition & Metabolic Disorders and Clinical Pharmacology Unit (CIRM), CHU Sart Tilman (B35), University of Liège, Liège B-4000, Belgium; andre.scheen{at}chu.ulg.ac.be
Citation
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease
Online issue publication
March 23, 2017
Article Versions
- Previous version (23 March 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/